Nasdaq: RGNX−38.15% 24h move
Price before$10.04May 13, 2026, 4:00 PM ET
First trade after$9.90May 14, 2026, 7:40 AM ET
24h later$6.21May 15, 2026, 7:09 AM ET
Complete Announced during: Premarket · announced Thu 7:15a ET (premarket); before = Wed close; first trade Thu 7:40a ET; time = SEC 8-K acceptance
REGENXBIO (Nasdaq: RGNX) reported topline results from a Phase 3 trial of RGX-202 on May 14, 2026. The company said the trial met its primary endpoint (p<0.0001).
Trial details
- Drug
- RGX-202Brand DUCHENNE
- Phase
- Phase 3
- Result
- Met endpointThe trial met its primary endpoint with high statistical significance (p<0.0001), with 93% of participants reaching at least 10% microdystrophin expression at Week 12 (n=30).p-value p<0.0001Figures as reported by the sponsor or registry; not calculated by DrugTrials.org.
- Safety
- “It’s encouraging to see robust microdystrophin expression, correlation with functional outcomes, and a manageable safety profile.
- Sponsor
- REGENXBIO Nasdaq: RGNX
- Dates
- Announced May 14, 2026, 7:15 AM ET (SEC 8-K filing time)
About this trial
This Phase 3 trial tested RGX-202 (DUCHENNE) in Duchenne Muscular Dystrophy. REGENXBIO reported that the trial met its primary endpoint (p-value: p<0.0001).
Sources
- Source: SEC EDGAR 8-K (EX-99.2)
For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.